Stem Cell Banking Market

Executive Summary

Stem Cell Banking Market was valued at US $7.38 billion in 2021 and is projected to grow at 8.47% CAGR over the forecast period to reach US $12.01 billion by 2027. Stem Cell Banking Market represented US $1.11 billion opportunity over 2019-2021 and estimated to create US $4.64 billion opportunity in 2027 over 2021.

Stem Cell Banking from Consainsights analyses the Stem Cell Banking Market in the Life Sciences industry over the forecast period to 2027.

Stem Cell Banking research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Stem Cell Banking segmentation includes Source, Service Type, Application, Region and Geography.

Based on the Source, the Stem Cell Banking analysis covers Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells (HESCS), Dental Pulp-Derived Stem Cells (DPSCS), Other Stem Cell Sources.

In Source segment, Bone Marrow-Derived Stem Cells (BMSCS) segment has highest cagr growth of 7.49%.

Based on the Service Type, the Stem Cell Banking analysis covers Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation.

In Service Type segment, Sample Preservation and Storage segment has highest cagr growth of 7.49%.

Based on the Application, the Stem Cell Banking analysis covers Personalized Banking Applications, Research Applications, Clinical Applications.

In Application segment, Personalized Banking Applications segment has highest cagr growth of 7.49%.

Based on the Region, the Stem Cell Banking analysis covers North America, Europe, Asia Pacific, RoW.

In Region segment, RoW segment has highest cagr growth of 7.49%.

Based on the region, the Stem Cell Banking analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Source

Introduction

In 2021, Placental Stem Cells (PSCS) segment has the highest revenue of US $2.81 billion and is expected to grow at CAGR of 7.49% by 2027 Bone Marrow-Derived Stem Cells (BMSCS) segment has highest cagr growth of 7.49%.

Placental Stem Cells (PSCS)

Placental Stem Cells (PSCS) segment was valued at US $2.39 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $4.58 billion by 2027. Placental Stem Cells (PSCS) segment represented US $0.42 billion opportunity over 2019-2021 and estimated to create US $1.77 billion opportunity in 2027 over 2021.

Adipose Tissue-Derived Stem Cells (ADSCS)

Adipose Tissue-Derived Stem Cells (ADSCS) segment was valued at US $1.61 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $3.09 billion by 2027. Adipose Tissue-Derived Stem Cells (ADSCS) segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.19 billion opportunity in 2027 over 2021.

Bone Marrow-Derived Stem Cells (BMSCS)

Bone Marrow-Derived Stem Cells (BMSCS) segment was valued at US $1.12 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.15 billion by 2027. Bone Marrow-Derived Stem Cells (BMSCS) segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.83 billion opportunity in 2027 over 2021.

Human Embryo-Derived Stem Cells (HESCS)

Human Embryo-Derived Stem Cells (HESCS) segment was valued at US $0.52 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.00 billion by 2027. Human Embryo-Derived Stem Cells (HESCS) segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.38 billion opportunity in 2027 over 2021.

Dental Pulp-Derived Stem Cells (DPSCS)

Dental Pulp-Derived Stem Cells (DPSCS) segment was valued at US $0.57 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.09 billion by 2027. Dental Pulp-Derived Stem Cells (DPSCS) segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.42 billion opportunity in 2027 over 2021.

Other Stem Cell Sources

Other Stem Cell Sources segment was valued at US $0.06 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $0.11 billion by 2027. Other Stem Cell Sources segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

Service Type

Introduction

In 2021, Sample Preservation and Storage segment has the highest revenue of US $3.58 billion and is expected to grow at CAGR of 7.49% by 2027 Sample Preservation and Storage segment has highest cagr growth of 7.49%.

Sample Preservation and Storage

Sample Preservation and Storage segment was valued at US $3.04 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $5.83 billion by 2027. Sample Preservation and Storage segment represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $2.25 billion opportunity in 2027 over 2021.

Sample Analysis

Sample Analysis segment was valued at US $1.07 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.04 billion by 2027. Sample Analysis segment represented US $0.19 billion opportunity over 2019-2021 and estimated to create US $0.79 billion opportunity in 2027 over 2021.

Sample Processing

Sample Processing segment was valued at US $1.45 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.77 billion by 2027. Sample Processing segment represented US $0.26 billion opportunity over 2019-2021 and estimated to create US $1.07 billion opportunity in 2027 over 2021.

Sample Collection and Transportation

Sample Collection and Transportation segment was valued at US $0.71 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.37 billion by 2027. Sample Collection and Transportation segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Personalized Banking Applications segment has the highest revenue of US $4.17 billion and is expected to grow at CAGR of 7.49% by 2027 Personalized Banking Applications segment has highest cagr growth of 7.49%.

Personalized Banking Applications

Personalized Banking Applications segment was valued at US $3.54 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $6.79 billion by 2027. Personalized Banking Applications segment represented US $0.63 billion opportunity over 2019-2021 and estimated to create US $2.62 billion opportunity in 2027 over 2021.

Research Applications

Research Applications segment was valued at US $1.57 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $3.00 billion by 2027. Research Applications segment represented US $0.28 billion opportunity over 2019-2021 and estimated to create US $1.16 billion opportunity in 2027 over 2021.

Clinical Applications

Clinical Applications segment was valued at US $1.16 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $2.22 billion by 2027. Clinical Applications segment represented US $0.20 billion opportunity over 2019-2021 and estimated to create US $0.86 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $3.92 billion and is expected to grow at CAGR of 7.49% by 2027 RoW segment has highest cagr growth of 7.49%.

North America

North America segment was valued at US $3.33 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $6.39 billion by 2027. North America segment represented US $0.59 billion opportunity over 2019-2021 and estimated to create US $2.47 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $1.76 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $3.38 billion by 2027. Europe segment represented US $0.31 billion opportunity over 2019-2021 and estimated to create US $1.30 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.88 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $1.70 billion by 2027. Asia Pacific segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.

RoW

RoW segment was valued at US $0.29 billion in 2019 and is projected to grow at 7.49% CAGR over the forecast period to reach US $0.55 billion by 2027. RoW segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.21 billion opportunity in 2027 over 2021.